Withings Launches Withings Medical, Onboarding First Patients on 8th July as the Only EU-Headquartered Company Selected for CMS’s New ACCESS Model in the US

Withings, the French connected health company founded in 2008, today announced Withings Medical, a new clinical care service marking the company’s move from monitoring health to delivering care. The service launches first for Medicare-eligible patients in the US, as part of CMS’s new ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions), a CMS Innovation Center initiative designed to pay for outcomes in chronic disease management and makes Withings the only EU-headquartered company selected for the model’s first cohort. At launch, Withings Medical focuses on cardiovascular and metabolic health, beginning with hypertension, diabetes and obesity, under the eCKM and CKM clinical tracks.

A European connected health pioneer

Withings was founded in Issy-les-Moulineaux, France, in 2008, and has spent nearly two decades building clinically validated, cellular-connected devices, smart scales with six-lead ECG, hybrid watches with cardiac monitoring, blood pressure monitors, sold in more than 30 countries. Its devices carry both FDA clearance and CE marking as a medical device manufacturer. Among the roughly 150 organisations selected for the ACCESS Model’s first cohort including US wearable and digital health names such as Whoop, Noom, Weight Watchers and Verily, Withings is the only company headquartered in Europe. That distinction extends beyond ACCESS membership: Withings is also the only European company advancing this next step in remote health monitoring, using AI to surface what matters in a patient’s data so clinicians spend their time on care, not on reviewing readings.

That EU regulatory grounding is central to how Withings is positioning itself inside ACCESS: not as a newcomer testing US healthcare for the first time, but as a company that has operated under Europe’s stricter medical-device and data-protection regimes for years, now applying that same clinical and engineering discipline to a US outcomes-based model.

Withings Medical treats the spectrum of cardiovascular-kidney-metabolic (CKM) conditions through the two levers that change a patient’s disease trajectory: guideline-directed medications and sustained lifestyle change. Care is delivered by Withings Medical Group, a dedicated clinical team that builds an individualised care plan for each member, prescribes and adjusts medications as conditions evolve, and supports day-to-day lifestyle change — all designed to integrate with the member’s existing primary care team.

Overview of the ACCESS Model
The Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model is a 10-year initiative from the CMS Innovation Center to modernize chronic disease management. Through a new “Outcome-Aligned Payment” system, it ties reimbursement to measurable improvements in patient health rather than the volume of services delivered. Under ACCESS, patients can benefit from technology-supported care in their everyday lives, often at low or no cost. The model is designed to expand patient choice, strengthen clinical accountability, and reduce Medicare spending. Major health plans representing 165 million Americans have committed to adopt an aligned payment model by 1st January 2028.

Why is this a big shift

For years, the technology to deliver virtual chronic care has been ready. The barrier was structural: payment models that paid for activity instead of outcomes, and distribution that reached patients through institutions rather than by their own choice. The ACCESS Model removes both barriers, rewarding better outcomes and giving patients a direct say in selecting their program. Withings Medical is what becomes possible when the payment and distribution model finally matches the technology that enables the care.

The GLP-1 trend

ACCESS is also launching into the fastest-moving trend in US chronic care: GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound, now used by roughly 11% of US adults for weight loss, up from about 3% in early 20241. That trend just hit Medicare directly — as of July 2026, CMS opened a short-term demonstration, the Medicare GLP-1 Bridge, giving eligible Part D beneficiaries access to these drugs for weight management for the first time3. It matters directly for ACCESS’s eCKM and CKM tracks, since 20% to 40% of GLP-1-driven weight loss is commonly estimated to be lean muscle rather than fat2, a real frailty and falls risk for older patients. Withings Medical monitors body composition to detect muscle loss, so its clinicians can manage GLP-1 treatment safely.

Nisha Basu, MD, MPH, Clinical Advisor, Withings Medical: “Millions of Americans live with chronic conditions and are unable to access consistent, high-quality care. Withings Medical changes that equation by combining three things that rarely come together: highly engaging, beautifully designed devices, decades of research to make those devices diagnostically accurate, and guideline-directed treatment for chronic disease. When engagement, clinical-grade measurement, and rigorous care converge in one experience, we can reach patients continuously rather than episodically.”

A new era of care, now underway in the US

Withings Medical marks the company’s move from monitoring health to delivering care. It will be available first through the ACCESS Model, the first outcome-based remote monitoring model of its kind, launched nationally in the United States on 5th July 2026, with a clinical focus on hypertension, diabetes, and obesity. Withings Medical onboarded its first patients on 8th July 2026. Participating in the ACCESS Model represents a vision for long-term health that Withings has long pursued.

To learn more about Withings Medical, or to see if you qualify for the ACCESS Model, visit withings.com/medical.